Health · Pharma & Biotech · 1 day ago
EU regulator rejects approval for cheaper cancer medicine developed by NKI
The Netherlands Cancer Institute (NKI) and KWF Cancer Control tried to bring a cancer medicine to market without help from large pharmaceutical companies.
Their effort to obtain approval from the European Medicines Agency, or EMA, has failed.
The aim was to offer a cheaper medicine.
The EMA’s decision means the medicine did not receive European approval through this process.
NKI had provided scientific evidence, according to a Dutch newspaper editor cited in the report.
But the approval requirements were substantially higher than the evidence provided could meet.
The sources do not say what the groups will do next.
The European Medicines Agency rejected approval for a cheaper cancer medicine developed by the Netherlands Cancer Institute and KWF Cancer Control.
The effort aimed to bring the medicine to market without cooperation from major pharmaceutical companies.
FD editor Thieu Vaessen said the NKI had provided scientific evidence.
He said the requirements for approval were substantially higher.
- Who
- The Netherlands Cancer Institute and KWF Cancer Control sought to bring the medicine to market; the European Medicines Agency rejected approval.
- What
- Approval was rejected for a cheaper cancer medicine developed by the NKI.
- When
- Not stated. The article was published on 10 October 2026.
- Where
- At the European Medicines Agency.
- Why
- The source says approval requirements were substantially higher, despite the NKI providing scientific evidence.
This story does not have two clearly opposing sides.
The NKI did provide scientific evidence, but the requirements for an approval process were substantially higher.
This story does not have a timeline yet.
- Medicine
- Cheaper cancer medicine
- Developer
- Netherlands Cancer Institute (NKI)
- Partner
- KWF Cancer Control
- Regulator
- European Medicines Agency (EMA)
- Article publication
- 10 October 2026
Sources
Related news
Experimental injection reduced visceral fat by 12% in early trials
AstraZeneca blames trial design for failed bone disease drug study
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
Experimental eye drops improve vision in a small study of a rare eye disease
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Taboos limit sales of weight-loss drugs in India despite obesity rates
Roche reports year-long results for eye drug Vamikibart
